Sukegawa-Hayasaka K, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu, Japan.
J Inherit Metab Dis. 2006 Dec;29(6):755-61. doi: 10.1007/s10545-006-0440-7. Epub 2006 Nov 7.
Mucopolysaccharidosis II (Hunter disease), a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), has variable clinical phenotypes. Nearly 300 different mutations have been identified in the IDS gene from patients with Hunter disease, but the correlation between the genotype and phenotype has remained unclear. We studied the characteristics of 11 missense mutations, which were detected in the patients or artificially introduced, using stable expression experiments and structural analysis. The mutants found in the attenuated phenotype showed considerable residual activity (0.2-2.4% of the wild-type IDS activity) and those in the severe phenotype had no activity. In immunoblot analysis, both the 73-75 kDa precursor and processed forms were detected in the expression of 'attenuated' mutants (R48P, A85T and W337R) and the artificial active site mutants (C84S, C84T). The 73-75 kDa initial precursor was detected in the 'severe' mutants (P86L, S333L, S349I, R468Q, R468L). The truncated 68 kDa precursor form was synthesized in the Q531X mutant. The results of immunoblotting indicated rapid degradation and/or insufficiency in processing as a result of structural alteration of the IDS protein. A combination of analyses of genotype and molecular phenotypes, including enzyme activity, protein processing and structural analysis with an engineered reference protein, could provide an avenue to understanding the molecular mechanism of the disease and could give a useful tool for the evaluation of possible therapeutic chemical compounds.
黏多糖贮积症II型(亨特氏病)是一种由艾杜糖醛酸-2-硫酸酯酶(IDS)缺乏引起的溶酶体贮积症,具有多种临床表型。在亨特氏病患者的IDS基因中已鉴定出近300种不同的突变,但基因型与表型之间的相关性仍不清楚。我们使用稳定表达实验和结构分析研究了在患者中检测到或人工引入的11种错义突变的特征。在症状较轻的表型中发现的突变体具有相当可观的残余活性(野生型IDS活性的0.2-2.4%),而在严重表型中的突变体则没有活性。在免疫印迹分析中,“症状较轻”的突变体(R48P、A85T和W337R)以及人工活性位点突变体(C84S、C84T)的表达中检测到了73-75 kDa的前体和加工形式。在“严重”突变体(P86L、S333L、S349I、R468Q、R468L)中检测到了73-75 kDa的初始前体。在Q531X突变体中合成了截短的68 kDa前体形式。免疫印迹结果表明,由于IDS蛋白的结构改变,导致其快速降解和/或加工不足。结合基因型和分子表型分析,包括酶活性、蛋白质加工以及使用工程参考蛋白进行结构分析,可为理解该疾病的分子机制提供途径,并可为评估可能的治疗化合物提供有用工具。